Perrigo Reports First Quarter 2021 Financial Results From Continuing Operations
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil slides following outreach to Iran to limit Houthis actions in Red Sea
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Perrigo (PRGO) Misses Q1 EPS by 7c, Revenues Miss; Offers FY21 EPS Mid-Point Guidance Above Consensus
May 11, 2021 6:32 AM EDTPerrigo (NYSE: PRGO) reported Q1 EPS of $0.50, $0.07 worse than the analyst estimate of $0.57. Revenue for the quarter came in at $1.01 billion versus the consensus estimate of $1.02 billion.
President and CEO, Murray S. Kessler commented, "Two years ago, we began our journey to transform Perrigo from a healthcare to a consumer self-care company and with the actions taken this quarter, that transformation is now nearly complete. On March 1, 2021, we announced the divestment of our generic Rx business, our tenth transaction over the last two years, essentially completing our portfolio reconfiguration. We have made the necessary... More
